†These authors contributed equally.
Background: Breast cancer is the most predominant tumor in women. Even
though current medications for distinct breast cancer subtypes are available, the
non-specificity of chemotherapeutics and chemoresistance imposes major obstacles
in breast cancer treatment. Although combretastatin A-4 (CA-4) has been
well-reported to have potential anticancer activity, in vivo studies of
CA-4 reveal a decrease in its activity. In this respect, a series of CA-4
analogues have been designed, from which one analog
[(1-(3-chloro-4-fluorophenyl)-N-(2methoxyphenyl)-5-(3,4,5-trimethoxyphenyl)-1H-1,2,4-triazole-3-carboxamide,
C